Rep. Gilbert Ray Cisneros, Jr. Sells Eli Lilly and Company (NYSE:LLY) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on March 13th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Eli Lilly and Company Trading Up 2.3%

NYSE:LLY opened at $952.24 on Thursday. The business’s 50-day moving average is $987.31 and its two-hundred day moving average is $973.10. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm has a market capitalization of $899.69 billion, a PE ratio of 41.49, a price-to-earnings-growth ratio of 1.09 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. During the same period last year, the company posted $5.32 earnings per share. The firm’s revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Trading of Eli Lilly and Company

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Exencial Wealth Advisors LLC raised its holdings in Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company’s stock worth $13,283,000 after purchasing an additional 11,396 shares during the period. Rede Wealth LLC acquired a new stake in Eli Lilly and Company in the third quarter worth $487,000. Central Pacific Bank Trust Division raised its holdings in Eli Lilly and Company by 25.8% in the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company’s stock worth $6,859,000 after purchasing an additional 1,843 shares during the period. Cidel Asset Management Inc. raised its holdings in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock worth $20,392,000 after purchasing an additional 5,591 shares during the period. Finally, Spire Wealth Management raised its holdings in Eli Lilly and Company by 2.2% in the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock worth $29,789,000 after purchasing an additional 592 shares during the period. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo (orforglipron) is now commercially available in the U.S.; Lilly is offering the oral GLP‑1 for obesity via LillyDirect and telehealth, with listed starter pricing of $25/month with commercial coverage and $149/month self‑pay — a revenue catalyst if uptake scales. Foundayo Now Available
• Positive Sentiment: CEO says the company is ready to scale production of the new weight‑loss pill, reducing supply‑risk concerns and supporting faster commercialization. CEO: Ready to Scale Production
• Positive Sentiment: Lilly expanded its Alzheimer’s R&D by amending the AC Immune tau collaboration to advance next‑gen tau aggregation inhibitors toward IND‑enabling studies — diversifies long‑term pipeline beyond obesity/diabetes. AC Immune Collaboration Extended
• Positive Sentiment: Guggenheim reiterated a bullish stance on Lilly ahead of Q1 results, providing analyst support that can buoy sentiment into earnings. Guggenheim Bullish Ahead of Q1
• Neutral Sentiment: Elevated investor attention and screen time on Lilly (search/coverage spikes) — increases short‑term volatility risk but not directionally decisive. Investors Heavily Search Lilly
• Negative Sentiment: Cheap generic GLP‑1 copies flooding India are already denting sales of Lilly’s Mounjaro there, signaling margin and volume pressure in an important growth market and a potential template for post‑patent competition elsewhere. India Generics Dent Sales Financial Post on India Copies
• Negative Sentiment: Pricing pressure from Novo Nordisk: a new high‑dose Wegovy launch is positioned significantly below Lilly’s equivalent pricing, intensifying competitive pricing pressure in the weight‑loss market. Novo Nordisk Undercuts Pricing
• Negative Sentiment: Recent analyst downgrade and critical investor questions have pressured near‑term sentiment, contributing to bouts of share weakness despite the product news. Analyst Downgrade

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 target price on shares of Eli Lilly and Company in a research report on Thursday, February 5th. Jefferies Financial Group set a $1,300.00 price objective on Eli Lilly and Company and gave the company a “buy” rating in a report on Friday, March 13th. Morgan Stanley reissued an “overweight” rating and issued a $1,313.00 price objective on shares of Eli Lilly and Company in a report on Thursday, March 5th. Wells Fargo & Company boosted their price objective on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,222.22.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.